trending Market Intelligence /marketintelligence/en/news-insights/trending/CtD0nepDff7fAshowQQjeg2 content esgSubNav
In This List

Revance Therapeutics prices public offering

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022


Revance Therapeutics prices public offering

Revance Therapeutics, Inc. priced an underwritten public offering of 5,338,709 common shares at $31 per share.

Of the total number of shares, the company will issue and sell 4,838,709 shares, and certain stockholders will sell 500,000 shares.

The company and the selling stockholders have granted the underwriters an option to buy up to an additional 800,806 shares.

Revance expects gross proceeds from the offering of about $150 million, excluding any exercise of the underwriters' option.

The offering is expected to close Dec. 11, subject to customary closing conditions.

Revance intends to use the net proceeds from the offering for general corporate purposes, including clinical trial and related expenses, research and development expenses, general and administrative expenses, and capital investments. It will not receive any proceeds from the sale of the shares by the selling stockholders.

Goldman Sachs & Co. LLC and Cowen are acting as book-running managers, Barclays is acting as joint lead manager, and Cantor Fitzgerald & Co., William Blair & Co. LLC and SunTrust Robinson Humphrey are acting as co-managers for the offering.